Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

49.08 -0.43 (-0.87%)
Delayed Quote Updated: 10:39 AM EST, Nov 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
45 46 Next >
News headline image
Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody ↗
The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have  
Via Benzinga
News headline image
GSK Trims Stake On Consumer Business Spin Off, Raises £804M ↗
GSK Plc (NYSE: GSK) sold 240 mi 
Via Benzinga
News headline image
Sanofi Says Its RSV Shot Significantly Cut Hospitalization Risk In Newborns ↗
The monoclonal antibody shot significantly reduced the risk of hospitalization in babies. 
Via Investor's Business Daily
News headline image
SpringWorks Therapeutics Announces Clinical Data Presentations of Nirogacestat in Combination with BCMA-Directed Therapies at the European Hematology Association 2023 Congress
From SpringWorks Therapeutics, Inc.
Via GlobeNewswire
News headline image
GSK Stock: A Value Trap or a Hidden Gem? ↗
GSK, formerly known as GlaxoSmithKline, is struggling after a complicated earnings season. Here's why GSK stock is still a buy. 
Via InvestorPlace
News headline image
GSK Clocks 10% Growth In Q1 Sales Excluding COVID-19 Products, Reaffirms Guidance ↗
 
Via Benzinga
News headline image
The FDA Just Approved an RSV Vaccine -- and It Isn't From Moderna or Pfizer ↗
RSV could be the next big battleground for big pharma -- but it could soon become crowded. 
Via The Motley Fool
News headline image
Dividend Income Update April 2023 ↗
With May already underway it is time for all dividend income investors to look back at the previous month and see how much passive dividend income their portfolios generated. 
Via Talk Markets
News headline image
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug 
Via MarketBeat
News headline image
WHO Ends Global Emergency Status for COVID-19 3 Years After Declaration, CDC Director Resigns ↗
The World Health Organization ended the global emergency 
Via Benzinga
News headline image
GSK: Add This Cheap Chip Play To Your Portfolio ↗
GSK pays a decent quarterly dividend. The latest declared dividend is $0.35 per share, giving GSK a yield of 3.85%. 
Via Talk Markets
News headline image
International Healthcare Week returns to showcase Hong Kong's strengths in healthcare innovation and investment
From HKTDC
Via ACN Newswire
News headline image
A Shot of Success: GSK's Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market ↗
The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in... 
Via Benzinga
News headline image
US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
From GSK plc
Via Business Wire
News headline image
GSK Stock Jumps After Beating Pfizer, Moderna To The RSV Vaccine Finish Line ↗
GSK won FDA approval for the first-ever RSV vaccine for older adults. 
Via Investor's Business Daily
News headline image
KVUE Stock: Should You Buy Into the Kenvue IPO? ↗
KVUE stock will be a dividend stock with an initial yield of 3.5%, with slow growth and lower margins than JNJ's drug business. 
Via InvestorPlace
News headline image
Pharma Giant Pfizer To Start Selling Haleon Stake Within Months, CFO Says ↗
Pfizer Inc (NYSE: PFE) is reportedly looking to start selling its stake in Haleon plc (NYSE: HLN).  
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE - UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review ↗
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
News headline image
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US ↗
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
News headline image
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost? ↗
The company reported lighter-than-expected declines due to Keytruda and Gardasil. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Biotechs That Might Get Bought Out in 2023 ↗
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
News headline image
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls ↗
Both GSK and Roche experienced declining Covid-related sales in the first quarter. 
Via Investor's Business Daily
News headline image
Was This Acquisition a Savvy Play by This Big Pharma Stock? ↗
The British drugmaker picked up a potential blockbuster drug in its deal for Bellus Health. 
Via The Motley Fool
News headline image
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value ↗
Cantor Fitzgerald has initiated coverage on Xenon Pharmaceuticals Inc (NASDAQ: XENE) with an Overweight rating and a  
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Spectrum Pharmaceuticals, Inc. (Nasdaq – SPPI), BELLUS Health Inc (Nasdaq – BLU), Prometheus Biosciences, Inc. (Nasdaq – RXDX), Univar Solutions Inc. (NYSE – UNVR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday ↗
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases. 
Via The Motley Fool
News headline image
Second Quarter Outlook For Biotech Stocks ↗
Biotech stocks have been consolidating recently but may be ready to rally higher due to factors such as a declining 10-year yield and growing M&A activity. 
Via Talk Markets
News headline image
Johnson & Johnson Unleashes Kenvue: Tylenol to Neutrogena, $40B Revenue Unit Spinoff Preps for IPO Blitz ↗
 
Via Benzinga
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
45 46 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.